Integrative deep learning strategies to enhance early-stage drug discovery: optimizing computational structure-activity modeling for pharmacotherapeutic innovation [0.03%]
Sarah Rezazi,Cherif Si-Moussa,Salah Hanini
Sarah Rezazi
The integration of computational intelligence into therapeutic development is increasingly important for accelerating early-stage drug discovery and improving compound prioritization. In this study, we developed an optimized neural network-...
Career commitment and professional satisfaction among Romanian pharmacy graduates: a nationwide cross-sectional survey [0.03%]
Marius Călin Cherecheş,Aura Rusu
Marius Călin Cherecheş
Introduction: Professional satisfaction is a key determinant of career commitment and workforce sustainability and retention in the pharmacy sector. The study examines professional satisfaction among Romanian pharmacy gra...
Rethinking asthma therapy, part 2: transdermal strategies for adjunct asthma and allergy treatments [0.03%]
从透皮策略入手重新考虑哮喘的治疗（第二部分）：联合使用透皮疗法治疗哮喘和过敏
Joseph Correa,Nicole K Brogden
Joseph Correa
Asthma and allergies affect millions of people globally. Avoiding triggers and allergens is a basic management technique for all asthma subtypes (>80% of asthma patients also suffer from allergies), and pharmacological treatment is the corn...
Rethinking asthma therapy, part 1: transdermal delivery of β2-agonists [0.03%]
哮喘治疗新思路（一）：β₂肾上腺素受体激动剂透皮给药疗法
Joseph Correa,Nicole K Brogden
Joseph Correa
Asthma and allergies are closely related conditions affecting millions of people around the world. Current treatment options cover many classes of drugs for both acute and ongoing conditions. β2-agonists, leukotriene modifiers, and cortico...
Editorial: Volume 2: real world evidence (RWE): paths to enhancing patient access to new medications [0.03%]
社论：第2卷：真实世界证据（RWE）：增强患者获取新药的途径
Allison Wills,Catherine Y Lau
Allison Wills
Corrigendum: Optimized Ginkgo biloba extract EGb 761®: boosted therapeutic benefits with minimized CYP enzyme interference [0.03%]
更正：优化的银杏叶提取物EGb 761：最大限度提高疗效，最小限度干扰CYP酶功能
Sunbeom Kwon,Suji Jeong,Seulah Lee
Sunbeom Kwon
[This corrects the article DOI: 10.3389/jpps.2025.14614.]. Keywords: CYP inhibition; EGb 761®; cognitive en...
The effect of cryoprotectant and storage conditions on the aggregation of poly(ethylene glycol)-poly(α-benzyl carboxylate-ε-caprolactone) nanoparticles [0.03%]
冻保护剂和储存条件对聚乙二醇-聚α-苄基焦谷酸-己内酯纳米粒子聚集的影响
Nasim Sarrami,Soheyla Honary,Mohammad Reza Vakili et al.
Nasim Sarrami et al.
Introduction: The preparation of nanoparticles (NPs) in aqueous media leads to thermodynamic instability and aggregation during storage. The objective of this study was to identify an optimum condition for the storage of ...
Targeted therapy and biomarker-guided applications of ecofriendly silver nanoparticles in precision oncology [0.03%]
用于精确诊断学的生物标志物导向型生态友好银纳米颗粒靶向疗法及应用
Haider Hamzah
Haider Hamzah
Eco-friendly silver nanoparticles (eco-AgNPs) represent a promising convergence of green nanotechnology and precision medicine for cancer treatment. This minireview examines the therapeutic potential of silver nanoparticles (AgNPs) synthesi...
Real-world safety profile of roflumilast: a pharmacovigilance analysis using FDA adverse event reporting system and Canada vigilance database [0.03%]
罗氟司特在真实世界中的安全特性：基于美国食品和药物管理局不良事件报告系统及加拿大监测数据库的药物流行病学分析
Rui Xu,Hui Peng,Chang Shu et al.
Rui Xu et al.
Background: Roflumilast, a highly selective phosphodiesterase 4 inhibitor, is used to treat with chronic obstructive pulmonary disease and psoriasis. We aim to determine potential roflumilast-associated adverse events (AE...
Enhancement of oral bioavailability of risedronate through xyloglucan rafts [0.03%]
黄原胶分子马达递药系统促进利塞磷酸盐口服吸收研究
Nader I Namazi,Rawan Bafail,Abdulkareem Ali Alanezi et al.
Nader I Namazi et al.
Bisphosphonates irritate the stomach and oesophagus and have a very limited absorption. The purpose of this study was to increase risedronate (RDN) oral bioavailability by causing a raft to form in the stomach. The creation of a raft preven...